In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ESC TV - Guidelines

News and opinion on the latest ESC Clinical Practice Guidelines

Watch now

2019 Guidelines on Dyslipidaemias (Management of)

ESC Clinical Practice Guidelines

These novel ESC/EAS Guidelines on lipids provide important new advice on patient management, which should enable more clinicians to efficiently and safely reduce CV risk through lipid modification.

These guidelines has been developed for healthcare professionals to facilitate informed communication with individuals about their CV risk and the benefits of adopting and sustaining a healthy lifestyle, and of early modification of their lipid-related CV risk.

Coronary Artery Disease (Chronic)
Cardiovascular Disease in Primary Care
Rehabilitation and Sports Cardiology
Basic Science
Treatment
Hypertension
Lipids
Risk Factors and Prevention
Cardiovascular Pharmacotherapy
Guidelines version available to download
Published in 2019
Reference Dyslip
Published in 2019
Reference Table of Contents
Published in 2019
Reference ESC/EAS Slides on Dyslipidaemias
App
Published in 2019
Reference Download the Pocket Guidelines App
Published in 2016
Reference 10.1093/eurheartj/ehw272 - European Heart Journal 2016
Published in 2011
Reference European Heart Journal (2011) 32:1769-1818
Published in 2011
Reference ESC/EAS Dyslipidemias addenda
Table of contents: Full Text (ESC Clinical Practice Guidelines)
  • Abbreviations and acronyms
  • Preamble
  • Introduction
    • What is new in the Guidelines?
  • What is cardiovascular disease prevention?
    • Definition and rationale
    • Development of the Joint Task Force Guideline for the Management of Dyslipidemias
  • Total cardiovascular risk
    • Total cardiovascular risk estimation
    • Risk levels
  • Lipids and lipoproteins
    • Biological role of lipids and lipoproteins
    • Role of lipids and lipoproteins in the pathophysiology of atherosclerosis
    • Evidence for the causal effects of lipids and lipoproteins on the risk of atherosclerotic cardiovascular disease
    • Laboratory measurement of lipids and lipoproteins
    • Recommendations for measuring lipids and lipoproteins to estimate the risk of atherosclerotic cardiovascular disease
  • Treatment targets and goals
  • Lifestyle modifications to improve the plasma lipid profile
    • Influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels
    • Influence of lifestyle on triglyceride levels
    • Influence of lifestyle on high-density lipoprotein cholesterol levels
    • Lifestyle recommendations to improve the plasma lipid profile
      • Bodyweight
      • Dietary fat
      • Dietary carbohydrate and fibre
      • Alcohol
      • Smoking
    • Dietary supplements and functional foods for the treatment of dyslipidaemias
      • Phytosterols
      • Monacolin and red yeast rice
      • Dietary fibre
      • Soy
      • Policosanol and berbine
      • n-3 unsaturated fatty acids
  • Drugs for treatment of dyslipidaemias
    • Statins
    • Cholesterol absorption inhibitors
    • Bile acid sequestrants
    • Proprotein convertase subtilisin/kexin type 9 inhibitors
    • Lomitapide
    • Mipomersen
    • Fibrates
    • n-3 fatty acids
    • Nicotinic acid
    • Cholesteryl ester transfer protein inhibitors
    • Future perspectives
    • Strategies to control plasma cholesterol
    • Strategies to control plasma triglycerides
  • Management of dyslipidaemias in different clinical settings
    • Familial dyslipidaemias
    • Women
    • Older people
    • Diabetes and metabolic syndrome
    • Patients with acute coronary syndromes and patients undergoing PCI
    • Stroke
    • Heart failure and valvular heart diseases
    • Chronic Kidney disease
    • Transplantation
    • Peripheral arterial disease
    • Other special population at risk of atherosclerotic cardiovascular disease
  • Inflammation
  • Monitoring of lipids and enzymes in patients on lipid-lowering therapy
  • Cost-effectiveness of cardiovascular disease prevention by lipid modification
  • Strategies to encourage the adoption of a healthy lifestyle
  • Changes and adherence to lipid-modifying therapies
  • Gaps in evidence
  • Key messages
  • Evidence-based "to do" and "not to do"
  • Supplementary data
  • Appendix
  • References